Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options

Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options

Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiac disease with a highly variable phenotypic expression, ranging from asymptomatic to drug refractory heart failure (HF) presentation. Pharmacological therapy is the first line of treatment, but options are currently limited to nons...

Full description

Bibliographic Details
Main Authors: Cristian Stătescu, Ștefana Enachi, Carina Ureche, Laura Țăpoi, Larisa Anghel, Delia Șalaru, Carmen Pleșoianu, Mădălina Bostan, Dragoș Marcu, Mircea Ovanez Balasanian, Radu Andy Sascău
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:International Journal of Molecular Sciences
Subjects:
hypertrophic cardiomyopathy
pharmacotherapy
drug trials
myosin inhibitors
mavacamten
Online Access:https://www.mdpi.com/1422-0067/22/13/7218

Similar Items

Similar Items